The Latest Breaking News from CRSP

Crispr Therapeutics reported its first profit in 10 quarters on Wednesday, but CRSP stock whipsawed.

Dow Jones futures: The market rally showed bullish breadth Monday, while Apple led six new buys. GE tumbled on guidance early Tuesday.

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.